Garden State Investment Advisory Services LLC Sells 130 Shares of Novo Nordisk A/S (NYSE:NVO)

Garden State Investment Advisory Services LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 5.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,143 shares of the company’s stock after selling 130 shares during the period. Garden State Investment Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $255,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in NVO. International Assets Investment Management LLC grew its holdings in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the period. DSM Capital Partners LLC boosted its position in shares of Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. Marshall Wace LLP increased its position in shares of Novo Nordisk A/S by 34,472.1% in the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock valued at $98,696,000 after buying an additional 689,441 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth $42,017,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $106.96 on Friday. Novo Nordisk A/S has a 12 month low of $96.53 and a 12 month high of $148.15. The company’s fifty day simple moving average is $110.59 and its 200-day simple moving average is $126.27. The firm has a market cap of $479.99 billion, a PE ratio of 34.61, a P/E/G ratio of 1.43 and a beta of 0.40. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NVO. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.